NASDAQ:AMGN - Amgen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $179.76 +3.40 (+1.93 %) (As of 04/24/2019 04:21 AM ET)Previous Close$176.36Today's Range$175.75 - $180.6352-Week Range$165.22 - $210.19Volume2.83 million shsAverage Volume3.05 million shsMarket Capitalization$110.72 billionP/E Ratio12.48Dividend Yield3.29%Beta1.21 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Receive AMGN News and Ratings via Email Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AMGN Previous Symbol CUSIP03116210 CIK318154 Webwww.amgen.com Phone805-447-1000Debt Debt-to-Equity Ratio2.36 Current Ratio2.79 Quick Ratio2.57Price-To-Earnings Trailing P/E Ratio12.48 Forward P/E Ratio12.88 P/E Growth2.17 Sales & Book Value Annual Sales$23.75 billion Price / Sales4.66 Cash Flow$18.3055 per share Price / Cash Flow9.82 Book Value$19.62 per share Price / Book9.16Profitability EPS (Most Recent Fiscal Year)$14.40 Net Income$8.39 billion Net Margins35.35% Return on Equity66.74% Return on Assets14.05%Miscellaneous Employees21,500 Outstanding Shares615,949,000Market Cap$110.72 billion Next Earnings Date4/30/2019 (Confirmed) OptionableOptionable Amgen (NASDAQ:AMGN) Frequently Asked Questions What is Amgen's stock symbol? Amgen trades on the NASDAQ under the ticker symbol "AMGN." How often does Amgen pay dividends? What is the dividend yield for Amgen? Amgen declared a quarterly dividend on Thursday, March 7th. Investors of record on Friday, May 17th will be paid a dividend of $1.45 per share on Friday, June 7th. This represents a $5.80 annualized dividend and a dividend yield of 3.23%. The ex-dividend date is Thursday, May 16th. View Amgen's Dividend History. How will Amgen's stock buyback program work? Amgen announced that its Board of Directors has approved a stock repurchase program on Friday, February 2nd 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued. How were Amgen's earnings last quarter? Amgen, Inc. (NASDAQ:AMGN) posted its earnings results on Tuesday, January, 29th. The medical research company reported $3.42 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.26 by $0.16. The medical research company earned $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same quarter in the previous year, the company posted $2.89 EPS. View Amgen's Earnings History. When is Amgen's next earnings date? Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for Amgen. What guidance has Amgen issued on next quarter's earnings? Amgen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $13.10-14.30 for the period, compared to the Thomson Reuters consensus estimate of $14.66. The company issued revenue guidance of $21.8-22.9 billion, compared to the consensus revenue estimate of $22.92 billion.Amgen also updated its FY 2019 guidance to $13.10-14.30 EPS. What price target have analysts set for AMGN? 17 equities research analysts have issued 12 month price targets for Amgen's shares. Their predictions range from $179.00 to $234.00. On average, they anticipate Amgen's share price to reach $207.7647 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Amgen. What is the consensus analysts' recommendation for Amgen? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen. What are Wall Street analysts saying about Amgen stock? Here are some recent quotes from research analysts about Amgen stock: 1. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019) 2. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019) 3. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019) Has Amgen been receiving favorable news coverage? Media stories about AMGN stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. Who are some of Amgen's key competitors? Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN) and Halozyme Therapeutics (HALO). What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Pfizer (PFE) and Celgene (CELG). Who are Amgen's key executives? Amgen's management team includes the folowing people: Mr. Robert A. Bradway, Chairman & CEO (Age 56)Mr. David W. Meline, Exec. VP & CFO (Age 62)Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)Mr. Esteban Santos, Exec. VP of Operations (Age 51)Mr. Mike Zahigian, Sr. VP & Chief Information Officer Who are Amgen's major shareholders? Amgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%), Strs Ohio (0.05%), Douglass Winthrop Advisors LLC (0.05%) and Bartlett & Co. LLC (0.05%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen. Which major investors are selling Amgen stock? AMGN stock was sold by a variety of institutional investors in the last quarter, including Merriman Wealth Management LLC, Abner Herrman & Brock LLC, South Texas Money Management Ltd., Pennsylvania Trust Co, Palisade Asset Management LLC, Tibra Equities Europe Ltd, LVM Capital Management Ltd. MI and Boston Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen. Which major investors are buying Amgen stock? AMGN stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., Pacer Advisors Inc., Cardinal Capital Management Inc., Manning & Napier Group LLC, Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV, Spectrum Management Group Inc. and Hennessy Advisors Inc.. View Insider Buying and Selling for Amgen. How do I buy shares of Amgen? Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amgen's stock price today? One share of AMGN stock can currently be purchased for approximately $179.76. How big of a company is Amgen? Amgen has a market capitalization of $110.72 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe. What is Amgen's official website? The official website for Amgen is http://www.amgen.com. How can I contact Amgen? Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected] MarketBeat Community Rating for Amgen (NASDAQ AMGN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 1,271 (Vote Outperform)Underperform Votes: 794 (Vote Underperform)Total Votes: 2,065MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: Is it Safe to Invest in Commodities?